Prostate cancer is the second most common malignancy in men worldwide, emphasizing the need for accurate, efficient, and accessible diagnostic methods. While multiparametric magnetic resonance imaging (mpMRI) is currently the gold standard for prostate cancer detection and risk stratification, it requires contrast administration, making it more costly and time-intensive.

Biparametric MRI (bpMRI), which excludes dynamic contrast-enhanced imaging, has emerged as a potential alternative, offering advantages such as shorter acquisition times and lower costs while still providing valuable diagnostic information. This study aims to evaluate the diagnostic performance of bpMRI in comparison with mpMRI for prostate cancer detection, with a particular focus on prostate volume measurement and PI-RADS scoring.